메뉴 건너뛰기




Volumn 43, Issue 1, 2002, Pages 121-126

Treatment of refractory peripheral T-cell lymphoma with denileukin diftitox (ONTAK®)

Author keywords

Cutaneous T cell lymphoma; DAB IL2; Denileukin diftitox; ONTAK ; Peripheral T cell lymphoma; Serum soluble IL 2 receptor

Indexed keywords

ALPHA INTERFERON; BEXAROTENE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DENILEUKIN DIFTITOX; DEXAMETHASONE; DIPHTHERIA TOXIN; DOXORUBICIN; ETOPOSIDE; HYBRID PROTEIN; IFOSFAMIDE; INTERLEUKIN 2; ISOTRETINOIN; LORATADINE; METHOTREXATE; METHYLPREDNISOLONE SODIUM SUCCINATE; NAVELBINE; PARACETAMOL; PELDESINE; PREDNISONE; PSEUDOEPHEDRINE; RETINOIC ACID; TEZACITABINE; TRIMETREXATE; VINCRISTINE; ANTINEOPLASTIC AGENT; INTERLEUKIN 2 RECEPTOR;

EID: 0036123178     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190210183     Document Type: Article
Times cited : (52)

References (20)
  • 3
    • 7344221466 scopus 로고    scopus 로고
    • "Peripheral T-cell lymphomas: Initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. classification"
    • (1998) Annals of Oncology , vol.9 , Issue.8 , pp. 849-855
    • Lopez-Guillermo, A.1    Cid, J.2    Salar, A.3
  • 9
    • 4243431287 scopus 로고    scopus 로고
    • Ontak (denileukin diftitox) product monograph
    • Ligand Pharmaceuticals.
    • (1999)
  • 16


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.